TNGNQ (Tengion) FCF Margin %: 0.00% (As of Sep. 2014)


What is Tengion FCF Margin %?

Tengion TNGNQ -99.00% FCF Margin % is 0.00% as of Sep. 2014.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tengion's Free Cash Flow for the three months ended in Sep. 2014 was $-4.40 Mil. Tengion's Revenue for the three months ended in Sep. 2014 was $0.00 Mil. Therefore, Tengion's FCF Margin % for the quarter that ended in Sep. 2014 was 0.00%.

As of today, Tengion's current FCF Yield % is 0.00%.

The historical rank and industry rank for Tengion's FCF Margin % or its related term are showing as below:


TNGNQ's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Tengion FCF Margin % Related Terms

Tengion FCF Margin % Historical Data

* Premium members only.

The historical data trend for Tengion's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tengion FCF Margin % Chart

Tengion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tengion Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TNGNQ vs VITIF, HSTC, NTRR: FCF Margin % Comparison

For the Biotechnology subindustry, Tengion's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tengion FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tengion's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tengion's FCF Margin % falls into.


Tengion FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tengion's FCF Margin for the fiscal year that ended in Dec. 2013 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2013 )/Revenue (A: Dec. 2013 )
=-17.259/0
= %

Tengion's FCF Margin for the quarter that ended in Sep. 2014 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2014 )/Revenue (Q: Sep. 2014 )
=-4.396/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Tengion (TNGNQ) has a FCF Margin % of 0.00% as of Sep. 2014. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tengion and its competitors.
Is Tengion's FCF Margin % too high?
Tengion's current FCF Margin % is 0.00%.
How does Tengion's FCF Margin % compare to VITIF and HSTC?
Tengion's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tengion and its competitors. Tengion's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tengion stock overvalued right now?
Tengion (TNGNQ) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Tengion (TNGNQ), the current FCF Margin % is 0.00% as of Sep. 2014. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tengion Business Description

Address 3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103
Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.